Author: Ungaro, Ryan C.; Agrawal, Manasi; Park, Sarah; Hirten, Robert; Colombel, Jeanâ€Frederic; Twyman, Kathryn; Gulko, Percio S.; Klang, Eyal
Title: Autoimmune and Chronic Inflammatory Disease Patients with COVIDâ€19 Cord-id: aqqfvbhh Document date: 2021_2_1
ID: aqqfvbhh
Snippet: OBJECTIVE: There are limited data on the impact of coronavirus disease 2019 (COVIDâ€19) on hospitalized patients with autoimmune and chronic inflammatory disease (AICID) compared with patients who do not have AICID. We sought to evaluate whether patients with AICID who have confirmed COVIDâ€19 presenting to the hospital are at higher risk of adverse outcomes compared with those patients without AICID who are infected with COVIDâ€19 and whether immunosuppressive medications impact this risk. M
Document: OBJECTIVE: There are limited data on the impact of coronavirus disease 2019 (COVIDâ€19) on hospitalized patients with autoimmune and chronic inflammatory disease (AICID) compared with patients who do not have AICID. We sought to evaluate whether patients with AICID who have confirmed COVIDâ€19 presenting to the hospital are at higher risk of adverse outcomes compared with those patients without AICID who are infected with COVIDâ€19 and whether immunosuppressive medications impact this risk. METHODS: We performed a multicenter retrospective cohort study with patients presenting to five hospitals in a large academic health system with polymerase chain reaction–confirmed COVIDâ€19 infection. We evaluated the impact of having an AICID and class of immunosuppressive medication being used to treat patients with AICID (biologics, nonbiologic immunosuppressives, or systemic corticosteroids) on the risk of developing severe COVIDâ€19 defined as requiring mechanical ventilation (MV) and/or death. RESULTS: A total of 6792 patients with confirmed COVIDâ€19 were included in the study, with 159 (2.3%) having at least one AICID. On multivariable analysis, AICIDs were not significantly associated with severe COVIDâ€19 (adjusted odds ratio [aOR] 1.3, 95% confidence interval [CI]: 0.9â€1.8). Among patients with AICID, use of biologics or nonbiologic immunosuppressives did not increase the risk of severe COVIDâ€19. In contrast, systemic corticosteroid use was significantly associated with an increased risk of severe COVIDâ€19 (aOR 6.8, 95% CI: 2.5â€18.4). CONCLUSION: Patients with AICID are not at increased risk of severe COVIDâ€19 with the exception of those on corticosteroids. These data suggest that patients with AICID should continue on biologic and nonbiologic immunosuppression but limit steroids during the COVIDâ€19 pandemic.
Search related documents:
Co phrase search for related documents- adjusted odd and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- adjusted odd and logistic regression model: 1, 2
- adjusted odd ratio and admission time: 1
- adjusted odd ratio and logistic regression: 1, 2, 3, 4, 5
- adjusted odd ratio and logistic regression model: 1, 2
- admission time and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- admission time and logistic regression model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- admission time and low possible: 1
- admit likely and logistic regression: 1
- logistic regression and low possible: 1, 2, 3, 4, 5, 6, 7
- logistic regression and low similar: 1, 2, 3, 4, 5
- logistic regression model and low possible: 1
- logistic regression model and low similar: 1
Co phrase search for related documents, hyperlinks ordered by date